2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2294

The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom
Abstract Number: 42

The Prevalence of Ankylosing Spondylitis in Sweden – a Nationwide Register Study
Abstract Number: 1087

The Prevalence of Knee Arthritis and Associated Self-Reported Limitation of Activity in Chinese Populations
Abstract Number: 1244

The Prevalence of Malignancy in Adult-Onset Still’s Disease
Abstract Number: 1413

The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis
Abstract Number: 1247

The Prevalence of Sacroiliitis and Spondyloarthritis in Patients with Sarcoidosis
Abstract Number: 1161

The Price of a Positive Test: Is It Worth the Cost?
Abstract Number: 1977

The Proangiogenic Function of the Epigenetic Regulator EZH2 in Synovial Tissue Is Mediated By Fibroblasts in Rheumatoid Arthritis
Abstract Number: 2638

The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies
Abstract Number: 1302

The Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus
Abstract Number: 1217

The Random Urine Uric Acid to Creatinine Ratio As a Predictor of 24-Hour Urine Uric Acid Excretion in Gout Patients
Abstract Number: 715

The REAL Life with Lupus Study: Developing a Patient Reported Outcome Measure for Use in Clinical Trials and Clinical Care
Abstract Number: 1218

The Reduction of Serum Uric Acid Level Might Prevent Atherosclerosis in Mice
Abstract Number: 1083

The Relation of Step Length to MRI Features of Osteoarthritis in the Patellofemoral Joint: The MOST Study
Abstract Number: 404

The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].